(vianews) - shares of erytech pharma (cac 40: eryp.pa) jumped by a staggering 11.44% to €0.76 at 13:56 est on friday, after four sequential sessions in a row of losses. cac 40 is sliding 0.28% to €7,005.98, following the last session's upward trend. this seems, at the moment, a somewhat bearish trend exchanging session today.
erytech pharma's last close was €0.68, 69.82% below its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-3.99.
volume
today's last reported volume for erytech pharma is 81651 which is 87.59% below its average volume of 658432.
moving average
erytech pharma's worth is way above its 50-day moving average of €0.65 and way below its 200-day moving average of €0.85.more news about erytech pharma (eryp.pa).